George Alexander J, Boehme Amelia K, Dunn Casey R, Beasley T, Siegler James E, Albright Karen C, El Khoury Ramy, Martin-Schild Sheryl
Stroke Program, Department of Neurology, Tulane University Hospital, New Orleans, LA, USA.
Int J Stroke. 2015 Jan;10(1):37-41. doi: 10.1111/ijs.12293. Epub 2014 Jun 3.
International management of acute ischemic stroke patients treated with intravenous tissue plasminogen activator frequently includes 24-h head imaging. These recommendations stem from the National Institute of Neurological Disorders and Stroke (NINDS) clinical trial protocol regarding the risk of intracerebral hemorrhage post-tissue plasminogen activator administration. Follow-up computed tomography scans on select patients, however, may not effect clinical management, resulting in unnecessary radiation exposure and healthcare costs.
Our study questions the utility of routine 24-h computed tomography imaging and looks at the National Institute of Health Stroke Scale as a possible clinical screen for selecting candidates for 24-h imaging. Such a tool would result in decreased radiation exposure to the patient and decreased cost to the hospital.
Consecutive patients with acute ischemic stroke given intravenous tissue plasminogen activator between June 2008 and December 2011 were retrospectively identified and dichotomized based on change in 24-h National Institute of Health Stroke Scale from baseline. Initial analysis compared patients with National Institute of Health Stroke Scale worsening to those without worsening. Subsequent analysis was limited to patients with a baseline National Institute of Health Stroke Scale ≤10. Baseline demographics and medical history, baseline and 24-h computed tomography findings, medical and/or surgical orders within six-hours of imaging, and antithrombotic administration within 24-48-h postintravenous tissue plasminogen activator were compared between the two groups.
Two-hundred patients met inclusion criteria: No 24-h National Institute of Health Stroke Scale worsening (n = 167) vs. 24-h National Institute of Health Stroke Scale worsening (n = 33). No baseline demographic or admission data differed significantly between the two groups. Patients without 24-h National Institute of Health Stroke Scale worsening had significantly lower incidence of hemorrhagic infarction (10·8% vs. 31·3%, P = 0·0014) on follow-up imaging. Less than 2% of all patients without 24-h National Institute of Health Stroke Scale worsening had a parenchymal hematoma. No patient with baseline National Institute of Health Stroke Scale ≤10 and without 24-h National Institute of Health Stroke Scale worsening had parenchymal hematoma. Patients with 24-h worsening were significantly less likely to receive timely antithrombotic therapy (60·6% vs. 77·8%, odds ratio 0·44, 95% confidence interval 0·20-0·96).
Our results demonstrate that routine 24-h computed tomography scan in patients without 24-h National Institute of Health Stroke Scale worsening (especially those with baseline National Institute of Health Stroke Scale ≤10) is less likely to yield information that results in a deviation from standard acute stroke care. No patient without worsening and baseline National Institute of Health Stroke Scale ≤10 had parenchymal hematoma on 24-h computed tomography. Application of the National Institute of Health Stroke Scale to distinguish patients who should have 24-h follow-up imaging from those who will not benefit is a potential avenue for improving utilization of resources and warrants further study.
急性缺血性脑卒中患者接受静脉注射组织型纤溶酶原激活剂治疗的国际管理方案通常包括24小时头部成像检查。这些建议源于美国国立神经疾病与中风研究所(NINDS)的临床试验方案,该方案涉及组织型纤溶酶原激活剂给药后脑内出血的风险。然而,对部分患者进行的后续计算机断层扫描可能不会影响临床治疗管理,从而导致不必要的辐射暴露和医疗费用。
我们的研究对常规24小时计算机断层扫描成像的效用提出质疑,并将美国国立卫生研究院卒中量表视为一种可能的临床筛查工具,用于选择进行24小时成像检查的患者。这样一种工具将减少患者的辐射暴露,并降低医院成本。
回顾性确定2008年6月至2011年12月期间接受静脉注射组织型纤溶酶原激活剂治疗的急性缺血性脑卒中连续患者,并根据24小时美国国立卫生研究院卒中量表相对于基线的变化进行二分法分类。初始分析比较了美国国立卫生研究院卒中量表恶化的患者与未恶化的患者。后续分析仅限于基线美国国立卫生研究院卒中量表≤10的患者。比较两组患者的基线人口统计学和病史、基线和24小时计算机断层扫描结果、成像后6小时内的医疗和/或手术医嘱,以及静脉注射组织型纤溶酶原激活剂后24 - 48小时内的抗栓治疗情况。
200例患者符合纳入标准:24小时美国国立卫生研究院卒中量表未恶化(n = 167)与24小时美国国立卫生研究院卒中量表恶化(n = 33)。两组之间的基线人口统计学或入院数据无显著差异。24小时美国国立卫生研究院卒中量表未恶化的患者在后续成像中出血性梗死的发生率显著较低(10.8%对31.3%,P = 0.0014)。在所有24小时美国国立卫生研究院卒中量表未恶化的患者中,实质性血肿的发生率不到2%。基线美国国立卫生研究院卒中量表≤10且24小时美国国立卫生研究院卒中量表未恶化的患者均无实质性血肿。24小时病情恶化的患者接受及时抗栓治疗的可能性显著降低(60.6%对77.8%,比值比0.44,95%置信区间0.20 - 0.96)。
我们的结果表明,对于24小时美国国立卫生研究院卒中量表未恶化的患者(尤其是基线美国国立卫生研究院卒中量表≤10的患者),常规24小时计算机断层扫描不太可能提供导致偏离标准急性卒中治疗的信息。没有病情恶化且基线美国国立卫生研究院卒中量表≤10的患者在24小时计算机断层扫描中无实质性血肿。应用美国国立卫生研究院卒中量表区分哪些患者应进行24小时随访成像,哪些患者不会从中受益,是提高资源利用效率的潜在途径,值得进一步研究。